Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:TSX:EPRX
日付受信時刻ニュースソース見出しコード企業名
2024/06/0706 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersTSX:EPRXEupraxia Pharmaceuticals Inc
2024/06/0706 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersTSX:EPRXEupraxia Pharmaceuticals Inc
2024/06/0520 : 00PR Newswire (US)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/06/0520 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/2406 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/2406 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/2220 : 00PR Newswire (US)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/2220 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/2206 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/2206 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/1420 : 00PR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/1420 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/0906 : 03PR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/0906 : 03PR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/0220 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
2024/05/0220 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/1120 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/1120 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/0820 : 00PR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/0820 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/0520 : 00PR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/0520 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/0406 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/0406 : 00PR Newswire (US)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/0206 : 01PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
2024/04/0206 : 01PR Newswire (US)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
2024/03/1222 : 41PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
2024/03/1222 : 39PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
2024/03/1205 : 06PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
2024/03/1205 : 04PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX

最近閲覧した銘柄